- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Clinical Significance of Tyrosine Kinase and Molecular Targeted Therapy in Pediatric Hematologic Disorders
-
- HAYASHI Yasuhide
- Department of Hematology/Oncology, Gunma Children's Medical Center
Bibliographic Information
- Other Title
-
- 小児造血器疾患におけるチロシンキナーゼの臨床的意義とその阻害剤による治療
Search this article
Description
Receptor tyrosine kinases are considered to play an important role for tumorigenesis. Among them, a class III receptor-type tyrosine kinase family, including FMS-like tyrosine kinase 3 (FLT3), stem cell factor receptor (KIT), and platelet-derived growth factor receptor (PDGFR), which is expressed on immature hemalopoiectic stem cells, plays an important role for cell growth, survival, differentiation, and migration. Recently, internal tandem duplication (ITD) and mutations of D835/I836 in the tyrosine kinase (TK) domain of the FLT3 gene have been reported in adult and pediatric acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), but not in acute lymphoblastic leukemia (ALL). The frequency and clinical significance of mutations of the FLT3, KIT, and PDGFRA genes are herereviewed in pediatric leukemias. Interestingly, FLT3 TK-mutations were found in about 20% of hyperdiploid ALL patients and infant ALL patients with MLL rearrangements. These ALL patients with mutations tended to have a poorer prognosis than those without the mutations. KIT mutations were found in 8 of 46 AML patients with t (8;21) out of 135 AML patients treated on the AML99 protocol. Mutations of PDGFRA gene were found in 2 of 114 AML patients in our study. These results suggested that mutations of the FLT3, KIT and PDGFRA genes may be one of the second hit mutations involved in the development of pediatric leukemia and are associated with specific chromosomal abnormalities. We also review here clinical significance of nucleophosmin and JAK genes which are associated with these tyrosine kinases. Recent progress of molecular targeted therapy against pediatric hematologic disorders wasalso reviewed.
Journal
-
- The Japanese Journal of Pediatric Hematology
-
The Japanese Journal of Pediatric Hematology 21 (3), 93-110, 2007
THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679320204928
-
- NII Article ID
- 130004345934
- 10020120837
-
- NII Book ID
- AN10080852
-
- ISSN
- 18844723
- 09138706
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed